Adjuvant systemic therapy is applied according to the estrogen receptor (ER) and progesterone receptor (PR), as well as the human epidermal growth factor receptor 2 (HER2), statuses and further depending on the tumor’s extent and nodal status [3]. This evidence concerns the gene ESR1 and neoplasm.